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Abstract
The role of ﬁtness in transmission of drug-resistant strains has been explored in previous studies; but has not been established for F15/
LAM4/KZN strains, which were responsible for the extensively drug-resistant tuberculosis (XDR-TB) outbreak in Tugela Ferry, South
Africa. The biological ﬁtness of 15 clinical strains representing the F15/LAM4/KZN, Beijing, F11 and F28 families was determined by growth,
viability and competition assays and correlated with DNA sequencing of eight genes associated with drug resistance and putative
compensatory mechanisms. Similar growth rates were observed among susceptible, multidrug-resistant (MDR) and XDR strains of the KZN
and F28 genotypes. In contrast, Beijing and F11 MDR strains demonstrated signiﬁcantly reduced ﬁtness. Resistant strains exhibited
heterogeneous ﬁtness proﬁles in competition with different susceptible strains, suggesting strain dependence. In addition, co-culture growth
rates were consistently higher than independent growth rates in 13/14 competition pairs. All 14 drug-resistant strains retained viability, at a
low CFU/mL, when paired with susceptible strains. The persistence of such resistant strains could consequently support the acquisition of
additional drug-resistance-conferring mutations and/or the evolution of compensatory mechanisms. Frequently occurring mutations were
detected in KZN and F28 resistant strains whereas, the Beijing MDR strain harboured a less common katG mutation and the F11 MDR
strain had no katG mutation. Contrary to drug-resistant Beijing and F11 strains, the successful transmission of KZN strains, particularly
during the outbreak, may be attributed to the presence of drug-resistance-conferring mutations associated with little or no associated
ﬁtness costs. Ampliﬁed growth in co-culture may be suggestive of in vivo trans-complementation.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB) represented 3.7%
of new cases and 20% of previously treated cases worldwide.
An alarming 9% of the average fraction of all these cases were
extensively drug-resistant (XDR) -TB [1]. South Africa, which
is ranked number 1 of 22 high TB-burdened countries globally,
reported 1.8% of new TB cases and 6.7% of previously treated
TB cases as MDR-TB [1]. Of these, 10% were XDR-TB, which
is among the highest, globally [2].
Mathematical models have predicted the successful spread
of drug-resistant Mycobacterium tuberculosis strains to be
dependent on strain ﬁtness [3]. The ﬁtness of a pathogen is
dependent on the rates at which drug-susceptible and
drug-resistant cell populations compete in an infected organ-
ism and the environment, are transmitted between organisms,
and are eliminated from infected organisms [4]. The magnitude
of these factors is variable depending on the degree and
pattern of antibiotic usage [4]. Drug-resistant strains often
demonstrate decreased competitive ability against susceptible
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strains in the absence of the drug [5]. This ﬁtness ‘cost’ is
dependent on strain genetic background and speciﬁc
drug-resistance-conferring mutations, which can be improved
by compensatory evolution [6].
The F15/LAM4/KZN genotype, ﬁrst detected in the
province of KwaZulu-Natal in the mid-1990s, was largely
associated with drug resistance [7]. The emergence of the
MDR forms of this genotype during the same period
coincided with increasing HIV prevalence rates and limited
access to antiretroviral treatment [7]. Second-line resistance
began to emerge between 1997 and 2000, followed by the
isolation of the ﬁrst XDR strain in 2001, preceding the
outbreak of the XDR-F15/LAM4/KZN strains in Tugela Ferry
in 2005 [8].
Between 2004 and 2005, the Beijing genotype accounted for
11% of MDR strains; the F11 genotype for 7% of all MDR and
10% of pre-XDR and XDR strains; and the F28 genotype
represented the highest proportion (49%) among the MDR,
30% of pre-XDR and 9% of the XDR strains in KwaZulu-Natal
(M. Pillay, personal communication).
Both MDR and XDR strains of F15/LAM4/KZN, F11 and
F28 are transmitted regardless of ﬁtness costs believed to
be associated with drug-resistance-conferring mutations [9].
In this study, we explore for the ﬁrst time, the ﬁtness of
the F15/LAM4/KZN, F11 and F28 families, compared with
the Beijing family, which has been previously extensively
characterized [10].Although it is not clear how accurately in
vitro ﬁndings correlate to in vivo conditions, laboratory data
can elucidate important information regarding resistance,
ﬁtness and compensatory mutations that may be conferred
in the natural environment [11]. The overrepresentation of
speciﬁc genotype families among cases of drug resistance
and the subsequent successful transmission of these strains
are of paramount importance in relation to TB control
regimens [12].
Methods and Materials
Mycobacterium tuberculosis isolates
The genotypes and the respective drug-resistance proﬁles of
the 15 clinical isolates included in this study are listed in
Table 1. Genotypes of the isolates were determined by
spoligotyping in previous studies as per the manufacturer’s
instructions (Isogen Bioscience B.V., Hyderabad, AP, India).
Drug susceptibility was determined using the 1% agar propor-
tion method [13].
Preparation of M. tuberculosis inoculum
Frozen stocks were prepared by inoculating 100 lL of each
strain into Middlebrook 7H9 broth (20 mL supplemented with
10% oleic albumin dextrose catalase (OADC), 0.05% Tween-80
and 0.5% glycerol). After aerobic incubation at 37°C, with
agitation, aliquots of 1000 lL were frozen once an optical
density at 600 nm (OD600) of 0.9–1.2 was reached. For the
growth and competition assays, frozen stocks were inoculated
into 100 mL of Middlebrook 7H9 broth in triplicate, incubated
with agitation at 37°C until until an OD600 of 1.6–1.8 was
reached. After centrifugation at 1780 g at 4°C for 10 min, the
pellet was washed twice with PBS containing 0.05% Tween-80
and re-suspended in 1 mL of Middlebrook 7H9 broth. Homo-
geneous suspensions were obtained by vigorous pipetting.
Fitness of axenic cultures
Re-suspended cultures were back-diluted, in triplicate, in
25 mL of Middlebrook 7H9 broth, to an OD600 of 0.015 using
the following formula: total OD units 9 (amount to
back-dilute) = (0.015) 9 (25 mL). The CFU/mL correspond-
ing to OD600 0.015 ranged from 3.65E + 05 to 3.10E + 06 for
all strains (see Supplementary material, Table S3). Cultures
were incubated aerobically with shaking at 37°C for 24 days.
TABLE 1. Genotype and drug susceptibility of clinical strains used in the study
Strain
Missing spoligo
spacers
ST
numbers Genotype family
Drug resistance
proﬁle Type
V9124 21–24, 33–36, 40 60 F15/LAM4/KZN None Susceptible
V4207 21–24, 33–36, 40 60 F15/LAM4/KZN None Susceptible
V1435 21–24, 33–36, 40 60 F15/LAM4/KZN IRS MDR
V2475 21–24, 33–36, 40 60 F15/LAM4/KZN IR MDR
KZN605 21–24, 33–36, 40 60 F15/LAM4/KZN IRSEOKCN XDR
X162 21–24, 33–36, 40 60 F15/LAM4/KZN IRSEOKCN XDR
B910 1–34 1 Beijing None Susceptible
B1528 1–34 1 Beijing None Susceptible
R35 1–34 1 Beijing IRS MDR
R283 1–34 1 Beijing IR MDR
R490 9–11, 21–24, 33–36 33 F11 None Susceptible
R271 9–11, 21–24, 33–36 33 F11 IR MDR
R104 9, 10, 33–36 34 F28 None Susceptible
R443 9, 10, 33–36 34 F28 IRON MDR
R262 9, 10, 33–36 34 F28 IRSEOKN XDR
I, isoniazid; R, rifampicin; S, streptomycin; E, ethambutol; O, oﬂoxacin; K, kanamycin; C, capreomycin; N, niacinamide, MDR, multidrug-resistant; XDR, extensively drug-resistant.
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Growth and metabolic activity were measured at 4-day
intervals for 24 days. In addition, OD600 measurements were
taken at 0, 24, 48 and 70 h during the lag phase. To ensure
reproducibility and accuracy, all measurements were recorded
in triplicate for each of the three biological replicates.
The CFUs were quantiﬁed in triplicate on Middlebrook
7H11 agar (containing 10% OADC, 0.05% Tween-80 and 0.5%
glycerol) after performing a ten-fold dilution series with PBS
(containing 0.05% Tween-80). For each strain family, the
resistant strains were compared with the susceptible strains by
a comparison of ﬁtness (W) [14].
W ¼ lnðRfinal  RinitialÞ=lnðSfinal  SinitialÞ
Where ln represents the natural logarithm and R and S
represent the CFU/mL of the resistant and susceptible strains,
respectively. The ﬁtness of the drug-susceptible strain repre-
sented 1. Therefore, if W < 1, then the resistant strain
encountered a ﬁtness cost, and if W > 1, then it was regarded
as ﬁt.
Alamar blue assay
Alamar Blue (Life Technologies, Fairland, Roosevelt Park,
South Africa) (10 lL) was added to 100 lL of culture in
triplicate in a clear 96-well microtitre plate. Broth and Alamar
blue alone served as negative controls and H37Rv and the
reagent represented the positive control. After aerobic
incubation overnight at 37°C, a colour change from blue to
pink was indicative of metabolically active cells. The absor-
bance was measured at 600 nm in the GloMax system
(Promega Corp., Madison, WI, USA), using Alamar Blue and
broth as a blank.
Pairwise competition
Cultures were back-diluted in duplicate into 30 mL of broth.
Thereafter, 10 mL each of a drug-susceptible and drug-resis-
tant culture were transferred into a 30-mL inkwell bottle,
resulting in a total of 20 mL each of mixed and single cultures.
OD600 and CFU counts were performed, in triplicate, at 6-day
intervals for 30 days on the aerobically agitated cultures at
37°C.
Counts of CFU were quantiﬁed in triplicate on Middlebrook
7H10 agar (containing 10% OADC, 0.05% Tween-80 and 0.5%
glycerol) with and without antibiotics. Plates containing
isoniazid (1 mg/L) and rifampicin (1 mg/L) were used to test
MDR isolates [13]. In addition, to these antibiotics, XDR
isolates were inoculated onto agar plates containing kanamycin
(5 mg/L) and oﬂoxacin (2 mg/L) [15].
After 21–25 days of aerobic incubation at 37°C, the number
of drug-resistant colonies (R) was counted on the antibiotic
plates. The number of drug-susceptible colonies (S) was
enumerated as the difference between the number of colonies
on the non-antibiotic and antibiotic plates. These colony
counts were then used to quantify the CFU/mL used to
calculate the mean competitive relative ﬁtness index (W) for
each drug-resistant strain.
PCR ampliﬁcation
A total of three susceptible, four MDR and three XDR clinical
isolates was examined for drug-resistance-conferring and
compensatory mutations by DNA sequencing. DNA was
isolated as described previously [15]. The primers listed in
Table 2 were used to amplify the following target genes: katG,
inhA, ahpC, rpoA, rpoB, rpoC, gyrA and rrs. PCR was performed in
a 25-lL mixture consisting of 0.25 mM dNTPs, each primer
(0.25 lM), 0.5 U of EconoTaq Polymerase (Lucigen), 19 PCR
buffer and 5 lL of template DNA. H37Rv was used as the
positive control and nuclease-free water as the negative
control. The thermal cycling conditions included denaturation
at 95°C for 10 min, followed by 40 cycles at 95°C for 20 s,
55°C for 1 min and 72°C for 30 s and a ﬁnal extension at 72°C
for 5 min. PCR products were visualized in 1.5% agarose gels
containing ethidium bromide using GeneSnap (SYNGENE).
DNA sequencing
Puriﬁcation and sequencing of the PCR products were
performed by Inqaba Biotec (Pretoria, South Africa) using
TABLE 2. Primer pairs and sequencing primer used for PCR
ampliﬁcation and DNA sequencing
Locus Nucleotide sequence (5′–3′)
Product
size
(base pairs) Reference
katGF GCAGATGGGGCTGATCTACG Zenteno-Cuevas
et al. (2009)
katGR AACTCGTCGGCCAATTCCTC 580 Zenteno-Cuevas
et al. (2009)
inhAF TGCAATT ATCCCAGCGAAG Primer 3 (v 0.4.0)
inhAR ACCGAAATGCAGGTAGTGCT 886 Primer 3 (v 0.4.0)
ahpCF GCGATGCCGATAAATATGGT Primer 3 (v 0.4.0)
ahpCR ATACCTGCGGATTTCGTGTC 877 Primer 3 (v 0.4.0)
rpoAF GAGTACTACTCAAAGTAAACCC Comas et al. (2012)
rpoAR CTTCTGATGTGAAGACGACC 1239 Comas et al. (2012)
rpoA AACAACTCGACCAGCGTCTT Sequencing
primer
Comas et al. (2012)
rpoBF TGGTCCGCTTGCACGAGGGTC van der Zanden
et al. (2003)
rpoBR CTCAGGGGTTTCGATCGGGCA 437 van der Zanden
et al. (2003)
rpoCF TCCGACTTGAACGACCTGTA Comas et al. (2012)
rpoCR GTTGCGCTCGTCGTGGTTCA 1298 Comas et al. (2012)
gyrAF CAGCTACATCGACTATGCGA Takiff et al. (1994)
gyrAR GGGCTCGGTGTACCTCAT 320 Takiff et al. (1994)
rrsIF AAGGGCTGCGATGCCGCGAG Primer 3 (v 0.4.0)
rrsIR AAGTCCGAGTGTTGCCTCAGG 433 Primer 3 (v 0.4.0)
rrs2F AGGTGTGGGTTTCCTTCCTT Primer 3 (v 0.4.0)
rrs2R CGTTGCTGATCTGCGATTAC 540 Primer 3 (v 0.4.0)
rrs3F CTGAGATACGGCCCAGACTC Primer 3 (v 0.4.0)
rrs3R TAAGGTTCTTCGCGTTGCATC 656 Primer 3 (v 0.4.0)
rrs4F GTGGCCGTTTGTTTTGTCAG Primer 3 (v 0.4.0)
rrs4R TGCAATATTCCCCACTGC 437 Primer 3 (v 0.4.0)
F, forward primer, R, reverse primer.
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the PCR forward primers, with the exception of the rpoA gene
for which a sequencing primer was synthesized (Table 2).
Termination reactions were performed using BigDye Termi-
nator v3.1 (ABI, Life Technologies). The labelled fragments
were puriﬁed using the Zymo Research Sequencing Clean-up
Kit and subsequently analysed in a 3500XL Genetic Analyzer
(ABI, Life Technologies). Multiple sequence alignment was
performed using BIOEDIT software. Due to the re-annotation of
the H37Rv genome [16], the new numbering system of the rrs
gene was used in this study.
Statistical analysis
All statistical analysis was performed using SPSS software
version 19.0 (IBM). One-way repeated measures analysis of
variance (ANOVA) was used for multiple comparisons of the
mean  SD obtained in the lag phase, OD and Alamar Blue
assays. One-way ANOVA was used to compare mean relative
competitive ﬁtness.
Results
Growth assays
OD assay. No signiﬁcant differences were found among any of
the resistant strains compared with susceptible ones during
the lag phase of growth (data not shown). Relatively similar
growth was observed among susceptible, MDR and XDR-F15/
LAM4/KZN strains (see Supplementary material, Figure S1).
However, both Beijing MDR strains (R35 and R283) presented
with a lower OD than the susceptible strains (B910 and
B1528). This was signiﬁcantly different between R35 and B910
(p 0.016), R283 and B910 (p 0.022) and R35 and R283
(p 0.046). Similarly, susceptible (S) strains F11-R490 and
F28-R104 demonstrated increased ﬁtness over MDR strains
F11-R271 (p 0.009) and F28-R443 (p 0.16), respectively.
CFU assay. In comparison to H37Rv, ﬁtness of three of the
four F15/LAM4/KZN drug-resistant strains was reduced (see
Supplementary material, Table S1). X162 (XDR) displayed
increased ﬁtness compared with both susceptible and refer-
ence strains, whereas KZN605 (XDR) was the least ﬁt of the
drug-resistant strains in all three comparisons. V1435 (MDR)
was only less ﬁt than H37Rv. V2475 (MDR) and KZN605
were signiﬁcantly less ﬁt than X162 relative to V4207 (S)
(p 0.017 and p 0.012, respectively) and H37Rv (p 0.012 and
p 0.008, respectively).
Beijing-R35 (MDR) was less ﬁt than Beijing-B1528 (S) and
H37Rv but not B910 (S). Beijing-R283 (MDR), however, was
ﬁtter than all three susceptible strains. No signiﬁcant differ-
ences were found between any of these comparisons.
F11-R271 (MDR) presented with ﬁtness costs compared
with F11-R490 and reference strain H37Rv. F28-R443 (MDR)
was marginally less ﬁt than R104 (S), but not less ﬁt than
H37Rv, whereas F28-R262 (XDR) was less ﬁt than both.
Alamar blue assay (supporting information). The Alamar Blue
assay showed similar metabolic activity for the F15/LAM4/
KZN strains, with signiﬁcant differences in viability only
between V4207 (S) and V2475 (MDR) (p 0.022). Among the
Beijing family, the viability of MDR strain R283 was signiﬁcantly
reduced compared with both susceptible strains, B910
(p 0.026) and B1528 (p 0.030). R35 (MDR) showed signiﬁ-
cantly lower ﬁtness than B910 (p 0.021) and B1528 (p 0.021).
Similar to the OD assay, the F11 strain R271 (MDR) displayed
signiﬁcantly reduced viability compared with R490 (S)
(p 0.004). Among the F28 family, although R104 (S) grew at
a consistently higher rate than R443 (MDR), it did not reach
signiﬁcance. R262 (XDR) displayed increased ﬁtness after day
12, with the exception of day 20, which suggests a pipetting
error.
Competitive growth. In pairwise competition experiments, sim-
ilar trends were observed in the OD and CFU assays (Fig. 1),
whereby the susceptible strain exhibited signiﬁcantly higher
growth (see Supplementary material, Figures S3–S8) than its
resistant counterpart throughout the experimental period. The
exception was the KZN-X162 (XDR), whose growth had
surpassed that of both the susceptible strains by day 30 of the
OD assay, but this was not statistically signiﬁcant. The growth of
this strain was almost identical to KZN-V9124 (S) until day18
(Fig. 1d) but lower than that of KZN-V4207 (S) in theCFU assay.
Optical density values for co-culture were consistently
higher than those of independent cultures (Fig. 1a,c and see
Supplementary material, Figures S3–S5) with the exception of
the Beijing pair, B1528 (S) + R283 (MDR). The growth of the
former was higher than in co-culture from day 12, but this was
not signiﬁcant.
All the KZN MDR, three of the four Beijing MDR and the
F11 MDR pairs experienced ﬁtness costs in competition with
susceptible strains (Fig. 2). In contrast, both KZN XDR strains
were ﬁt. The F28 XDR strain exhibited a minimal competitive
cost paired with R104 (S). Higher ﬁtness indices were
observed for all KZN MDR and XDR strains when paired
with V9124 (S) compared with V4207 (S), and for Beij-
ing-resistant strains when paired with B1528 (S) compared
with B910 (S). This difference was statistically signiﬁcant
between the KZN605 (XDR) pairs (p 0.017). Furthermore,
R283 (MDR) (paired with B1528) was the ﬁttest strain among
the four genotype families, whereas the F11 strain R271
(MDR) was the least ﬁt.
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Molecular characterization. Eight genes associated with drug
resistance were sequenced in eleven clinical strains and H37Rv
on day 12 of the growth assays. Multiple sequence alignment
with H37Rv in Tuberculist showed no differences between
both reference strains. Sequencing detected four different
mutations in rpoB, two in gyrA and katG, one in rpoC and rrs,
and none in rpoA, inhA or ahpC (Table 3). Identical mutations
were present in both KZN and the F28 XDR strains: double
mutations Asp516Gly/Leu533Pro in rpoB and Ala90Val/
Ser95Thr in gyrA, and single mutations Ser315Thr in katG,
A1402G in rrs and Ala542Ala in rpoC. Different rpoB mutations
were harboured in the three MDR strains belonging to the
different families. However, Ser531Leu in rpoB was common to
both MDR F11 and Pre-XDR F28. All drug-resistant KZN and
F28 harboured Ser315Thr, whereas Beijing harboured Ser315-
Asn in katG. Ser95Thr in gyrA was present in all sensitive
strains, in addition to Ala542Ala in rpoC KZN.
Discussion
From an epidemiological perspective, the principal dynamic
that impacts the spread of drug-resistant strains is the ﬁtness
cost associated with the resistance mutations they harbour
[17]. In our study, MDR and XDR strains representing the F15/
LAM4/KZN and F28 genotypes demonstrated enhanced ﬁtness
despite the burden of carrying drug-resistance-conferring
mutations. In contrast, Beijing and F11 MDR strains exhibited
signiﬁcantly reduced ﬁtness.
All the F15/LAM4/KZN, Beijing and F28 resistant strains had
a ﬁtness index above 0.7 in the CFU growth and competition
assays, with the exception of KZN605 and V2475, which had
ﬁtness indices of 0.61 and 0.65, respectively, in competition
with V4207. Hypothetically, co-infection with V4207 may
impede the successful spread of these two resistant strains to
other hosts, unless selected for by antibiotic pressure. The
mean ﬁtness of 0.44  0.13 of F11-R271 (MDR) in pairwise
competition is hardly surprising, given its reduced growth in
axenic cultures (see Supplementary material, Figures S1 and
S2). Therefore, this strain would not be expected to spread
successfully in the population.
Pairwise competition revealed three generalized patterns of
growth. First, there was an ‘overgrowth’ of susceptible strains
in the CFU results obtained, most likely attributable to
differences in ﬁtness between co-infecting susceptible and
resistant strains [10,18]. However, all 14 drug-resistant strains
(a)
(c)
(b)
(d)
FIG. 1. Optical density (OD) measurements and CFU counts for competitive KZN strain pairs. (a) OD values and (b) CFU/mL for V9124
(S) + V1435 (MDR). (c) OD values and (d) CFU/mL for V9124 (S) + X162 (XDR). Data are represented as the mean  SD of duplicate
experiments. S: susceptible; MDR, multidrug-resistant; XDR, extensively drug-resistant.
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retained viability, at a low CFU/mL, when paired with
susceptible strains. The persistence of such resistant strains
could consequently support the acquisition of additional drug
resistance-conferring mutations and/or the evolution of
compensatory mechanisms.
Second, ﬁtness proﬁles of the F15/LAM4/KZN and Beijing
resistant strains during competition were heterogeneous, i.e.
all the former strains had higher ﬁtness paired with
KZN-V9124 (S) compared with KZN-V4207 (S), with signif-
icant differences between both KZN605 (XDR) pairs
(p 0.022). Similarly, the Beijing MDR strains had higher ﬁtness
with B910 (S) compared to B1528 (S). This is most likely due
to ﬁtness differences between susceptible strains. Together,
the results are suggestive of strain dependence. Lastly, growth
in co-culture was ampliﬁed compared with single cultures in 13
of 14 competition pairs. To the best of our knowledge,
this phenomenon in co-culture noted after 2 weeks of growth,
has not been reported in M. tuberculosis before. We hypo-
TABLE 3. Distribution of non-synonymous and synonymous mutations in selected clinical strains
Strain Genotype family
Resistance
proﬁlea rpoA rpoB rpoC katG inhA ahpC gyrA rrs
V9124 F15/LAM4/KZN None – – Ala542Ala – – – Ser95Thr –
V2475 F15/LAM4/KZN IR – Asp516Tyr Ala542Ala Ser315Thr – – Ser95Thr –
KZN605 F15/LAM4/KZN IRSEOKCN – Asp516Gly; Ala542Ala Ser315Thr – – Ala90Val; A1402G
Leu533Pro Ser95Thr
X162 F15/LAM4/KZN IRSEOKCN – Asp516Gly; Ala542Ala Ser315Thr – – Ala90Val; A1402G
Leu533Pro Ser95Thr
B910 Beijing None – – – – – – Ser95Thr –
R35 Beijing IRS – Leu533Pro – Ser315Asn – – Ser95Thr –
R490 F11 None – – Ala542Ala – – – Ser95Thr C492T
R271 F11 IR – Ser531Leu Ala542Ala – – – Ser95Thr C492T
R104 F28 None – – – – – – Ser95Thr –
R443 F28 IRSEK – Ser531Leu – Ser315Thr – – Ser95Thr –
R262 F28 IRSEOKN – Asp516Gly; Ala542Ala Ser315Thr – – Ala90Val; A1402G
Leu533Pro – Ser95Thr
H37Rv Laboratory strain None – – – – – – – –
aI, isoniazid; R, rifampicin; S, streptomycin; E, ethambutol; O, oﬂoxacin; K, kanamycin; C, capreomycin; N, niacinamide.
FIG. 2. Mean competitive relative ﬁtness for KZN, Beijing, F11 and F28 drug-resistant strains. The ﬁtness index of the susceptible strain is taken as
1 (solid black line). Fitness indices below 1 indicate ﬁtness costs and ﬁtness indices above 1 indicate no loss of ﬁtness. The data above are represented
as the mean  SD of duplicate experiments. MDR, multidrug-resistant; XDR, extensively drug-resistant.
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thesize that one strain may be promoting or suppressing the
growth of the other by means of a putative growth factor, or
other signalling molecules. In contrast, Bhatter et al. [14]
recently showed mutual inhibition of growth of susceptible and
resistant strains from the MANU genotype during a compe-
tition assay. Hence, differences in competitive behaviour may
be a reﬂection of biological differences between strain
genotypes.
The high frequency of Ser315Thr katG mutations in clinical
isolates in our study illustrate its importance in conserving
catalase/peroxidase activity, virulence and reduced conversion
of isoniazid into active form, while maintaining mycobacterial
ﬁtness [19]. The Beijing MDR strain, however, harboured a
different mutation (Ser315Asn) in katG. This mutation,
although associated with a small reduction (4%) in virulence,
presented with signiﬁcantly reduced catalase–peroxidase activ-
ity compared with four other katG mutants, including the
Ser315Thr mutant, in a study by Unissa et al. [20]. The
presence of the Ser315Asn mutation could consequently
explain the reduced ﬁtness of Beijing-R35 (MDR) in all the
assays.
All seven resistant strains harboured mutations in the
sequenced 81-bp hot-spot region of rpoB that accounts for
>95% of rifampicin resistance in clinical M. tuberculosis strains
[21]. The XDR strains harboured a common mutation
(Asp516Gly) that was distinguishable from the MDR F15/
LAM4/KZN strain (Asp516Tyr). This supports the ﬁndings of
others that propose independent acquisition of rpoB mutations
for MDR and XDR F15/LAM4/KZN strains [22]. In addition to
Asp516Gly, the XDR strains possessed a second rpoB muta-
tion at codon 533, identical to the mutation present in the
Beijing MDR strain.
The F11 and F28 MDR strains possessed the most
frequently occurring rifampicin resistance-conferring mutation,
Ser531Leu associated with minimal or no ﬁtness loss in clinical
isolates [21,23]. Taken together with the Ser315Thr mutation
in katG, the increased ﬁtness of F28-R443 (MDR) in the OD,
Alamar Blue and CFU assays can be attributed to its
predisposition to ‘beneﬁcial’ ﬁtness mutations in rpoB and
katG. Despite the presence of Ser531Leu in F11-R271 (MDR),
it grew poorly in comparison to the susceptible strain in the
growth and competition assays. The reduced ﬁtness of this
strain may be attributed to an unidentiﬁed katG mutation that
it may harbour, which may be slowing down its growth despite
the beneﬁcial rpoB mutation it possesses.
No mutations were detected in the inhA sequenced region
in any of the isolates. Mutations have been reported in the inhA
promoter region for KZN-V2475 (MDR) and another F15/
LAM4/KZN XDR strain, KZN-R506 [22]. However, we had
not sequenced this region because of ﬁnancial constraints. No
putative compensatory mutations were detected in the ahpC,
rpoA or rpoC genes for any clinical strain. However, there could
be other mechanisms of compensation for which whole
genome sequencing could provide more insight. The presence
of synonymous mutation Ala542Ala in rpoC for F15/LAM4/
KZN strains, F11 strains and F28-R262 (XDR) is in accordance
with a recent study that demonstrated this mutation in Lineage
4 strains only [24]. A natural polymorphism, thought to be
unassociated with ﬂuoroquinolone susceptibility [25], was
observed at codon 95 of gyrA in all 11 clinical strains. In
addition, both resistant and susceptible F11 strains possessed
the C492T polymorphism in rrs, which is useful as a
phylogenetic marker for such strains [26].
Identical mutations were detected in katG (Ser315Thr), rpoB
(Asp516Gly, Leu533Pro), rpoC (Ala542Ala), gyrA (Ala90Val,
Ser95Thr) and rrs (A1402G) for all three XDR strains. This is
supported by whole genome sequencing of M. tuberculosis
XDR strains that revealed only a few differences among them
[22]. These mutations that confer resistance to ﬁrst- and
second-line drugs appear to be favourable to the XDR
organisms, as displayed by their unimpeded growth in the
growth and competition assays of this study. A recent
comparison of the XDR strains from the Tugela Ferry
outbreak to a panel of phylogenetically distinct drug-resistant
and susceptible strains of M. tuberculosis showed very little
substantiation for compensatory mechanisms [27]. This has
signiﬁcant implications for the pathogenicity and transmissibil-
ity of these strains, which carry mutations in several essential
genes. The possibility arises that these strains may be more
suited to compromised populations, including HIV-infected
individuals, in which the organism’s minimal ﬁtness costs are
negligible.
There are a few limitations of this study. First, only
co-cultures were plated out and we were therefore unable
to correlate these ﬁndings with axenic susceptible and
resistant CFU counts in the competition assays. Second, only
a limited number of genes and gene regions could be
sequenced in this study. Therefore, other signiﬁcant mutations
correlating with observed ﬁtness phenotypes may have gone
undetected.
In conclusion, paired growth of competing resistant and
susceptible strains illustrated a slight ‘additive’ effect in
comparison to independent growth. This in vitro ﬁnding may
be postulated to represent an in vivo occurrence with
implications in high-incidence TB settings, including South
Africa, that are burdened with a wide spectrum of strain
diversity and drug resistance. Furthermore, strains with
differing drug-resistance phenotypes [28] and strain genotypes
[29] have been found to co-exist in hosts in South Africa. Our
ﬁndings demonstrate that the successful spread of F15/LAM4/
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KZN strains during the Tugela Ferry XDR-TB outbreak in
2005 may be attributed to the presence of drug resis-
tance-conferring mutations associated with little or no ﬁtness
cost. This conclusion is in agreement with previous observa-
tions that drug-resistant F15/LAM4/KZN strains are highly
transmissible [7] and highlights the importance of TB surveil-
lance systems, which may prevent future epidemics caused by
ﬁt resistant strains.
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